Last updated: June 20, 2026
Suppliers for lidocaine hydrochloride 0.2% in dextrose 5% (D5W) typically fall into two buckets: (1) sterile injectable drug product manufacturers that fill-finish the ready-to-use solution and (2) upstream suppliers for key inputs such as lidocaine HCl API, dextrose monohydrate, sterile water for injection (WFI), and container-closure systems.
No complete, reliable supplier list can be produced from the information provided because “Lidocaine HCl 0.2% in D5W” can map to multiple NDC configurations, strength/concentration interpretations, and presentation types (premix bag vs unit-dose vial vs compounded preparation), each with different source options and regulatory status.
What are the main supplier categories for lidocaine hydrochloride 0.2% in dextrose 5%?
Featured snippet answer: The relevant supply chain segments are API, sterile compounding/fill-finish, and sterile infusion packaging.
API and excipients: who supplies the core inputs?
For this sterile IV solution, upstream supply typically includes:
- Lidocaine hydrochloride (API): API manufacturers or API distributors that support sterile drug product production
- Dextrose monohydrate (USP grade) and associated control/traceability
- Sterile water for injection (WFI)
- Container-closure components that maintain sterility and compatibility (bags, seals, ports, secondary overwrap)
Sterile drug product supply: who makes the ready-to-use solution?
The direct supplier most relevant to purchasing is usually a firm that can perform:
- Aseptic manufacture and sterile filtration/aseptic fill
- Final drug product release for IV infusion use
- Packaging and labeling in the specific NDC/presentation format requested
Compounding/outsourcing: who supplies when there is no commercial premix?
Where commercial premix availability is limited, some supply comes from:
- Outsourcing facilities or hospital/clinic in-house compounding using validated sterile compounding processes
These sources depend on whether a specific NDC/premix exists in the market.
Which companies supply the lidocaine HCl 0.2% in D5W premix market?
Featured snippet answer: The supplier set depends on NDC and presentation (bag size, vial size, single- vs multi-dose). Without the specific product identifier(s), a deterministic company list cannot be generated.
Why NDC mapping matters
“Lidocaine hydrochloride 0.2% in dextrose 5%” can correspond to multiple:
- NDCs
- package sizes (e.g., 100 mL, 250 mL, 500 mL bags)
- unit dose formats
- manufacturer labels that change supply chain partners
Supplier identity is usually tied to the labeler of record and the finished dose manufacturer rather than the raw formulation string.
What to look for in supplier due diligence
When identifying suppliers for procurement or qualification, the relevant fields are:
- Labeler/marketed product manufacturer
- Aseptic fill-finish location
- Sterility assurance documentation and batch release test panel
- Container-closure system compatibility with lidocaine and D5W
- Chain of custody for API and excipients
How do suppliers differ by container-closure (IV bag vs vial) for this solution?
Featured snippet answer: Container type drives the list of qualified suppliers and packaging vendors.
IV bag suppliers
Common bag systems include:
- Flexible plastic infusion containers
- Overwrap and port systems for aseptic handling
Vial suppliers
Unit-dose vials require:
- Different closure systems
- Different fill volumes and overwrap approaches
- Different handling and withdrawal devices
Procurement specifications determine which supplier list applies.
What regulatory status does a commercial supplier need for lidocaine HCl 0.2% in dextrose 5%?
Featured snippet answer: A commercial premix supplier needs FDA marketing authorization consistent with its product type, typically reflected in FDA drug listings and labeling.
Orange Book vs non-Orange Book
This formulation may be marketed as:
- An FDA-approved sterile injectable (premix), which appears in relevant FDA databases
- A compounded product from an outsourcing facility, which is not the same as an approved NDA/ANDA listing
Your ability to buy from a given supplier depends on the regulatory route the supplier uses to market or compound the product.
Quality systems expected from suppliers
A qualified supplier generally can provide:
- GMP compliance
- Sterility assurance controls
- Stability protocol and expiration dating
- Component traceability for API and excipients
What generic/alternative suppliers exist if a specific NDC is constrained?
Featured snippet answer: Alternative supply usually means switching either NDC labeler or presentation/format while keeping the same active concentration and solvent system.
Substitution risks suppliers should address
Even with the same label claim, substitution can change:
- Fill volume
- pH
- container materials
- osmolarity
- withdrawal devices and compatibility
A procurement and substitution decision should be based on the specific product identifier, not only the formulation string.
What sourcing barriers affect availability of lidocaine HCl 0.2% in D5W?
Featured snippet answer: Supply is constrained by aseptic manufacturing capacity, API availability, and packaging availability.
Capacity constraints
Sterile premix lines can have:
- Limited changeover flexibility
- Batch schedule constraints driven by sterility testing timelines
Component constraints
Bottlenecks commonly include:
- API lead times
- dextrose and WFI production capacity
- bag/closure component availability and compatibility testing
Key Takeaways
- Supply for lidocaine hydrochloride 0.2% in dextrose 5% is typically sourced from (1) sterile injectable premix manufacturers and (2) upstream API/excipient and packaging suppliers.
- A precise, usable supplier list requires product-specific identifiers (at minimum the exact NDC/presentation or equivalent listing-level identifiers). Without those, any named supplier set would be incomplete and potentially incorrect.
- Supplier selection should be tied to aseptic capability, sterility assurance, container-closure compatibility, and FDA listing/regulatory route for the specific marketed product.
FAQs
- How do I find the approved manufacturers for lidocaine HCl 0.2% in dextrose 5% by NDC?
- Are compounding suppliers able to supply lidocaine hydrochloride 0.2% in D5W for IV infusion when commercial premix is unavailable?
- What excipient grades are typically required for sterile lidocaine in D5W manufacturing?
- Does container type (bag vs vial) affect compatibility for lidocaine in D5W?
- What documentation should be requested from suppliers for sterile drug product release and stability?
References
(No sources cited because no product identifier, regulatory listing, or supplier directory content was provided.)
